Cost effectiveness of emedastine versus levocabastine in the treatment of allergic conjunctivitis in 7 european countries

PharmacoEconomics

Volumn 19, Issue 3, 2001, Pages 255-265

  Pinto, Carlos Gouveia ^a   Lafuma, Antoine ^b   Fagnani, Francis ^b   Nuijten, Mark J C ^c   Berdeaux, Gilles ^d  

^a NONE   (France)

^b CEMKA EVAL   (France)

^c NONE   (Netherlands)

^d Alcon France   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; EMEDASTINE; LEVOCABASTINE;

ALLERGIC CONJUNCTIVITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EUROPE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESOURCE ALLOCATION; TREATMENT FAILURE;

BENZIMIDAZOLES; CONJUNCTIVITIS, ALLERGIC; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; HEALTH CARE COSTS; HISTAMINE H1 ANTAGONISTS; HUMANS; PIPERIDINES;

EID: 0035083352     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119030-00004     Document Type: Article

References (73)

1. Immunology of the external ocular tissues
2. Epidemiology of hay fever and perennial allergic rhinitis
3. Development of atopic disease in relation to family history and cord blood IgE levels
4. Allergic conjunctivitis
5. The prevalence and incidence of asthma and asthma-like symptoms in a general population sample
6. Perennial allergic conjunctivitis: Definition, clinical characteristics and prevalence. A comparison with seasonal allergic conjunctivitis
7. Diagnosis of allergic conjunctivitis
8. Levocabastine eye drops: A new approach for the treatment of allergic conjunctivitis
9. The role of levocabastine in the treatment of allergic rhinoconjunctivitis
10. Validation of the standardized version of the Rhino-conjunctivitis Quality of Life Questionnaire
11. Relationship between nasal hyperreactivity, quality of life, and nasal symptoms in perennial rhinitis
12. Cots of hay fever in the United States in 1990
13. Clinical evaluation of twice daily emedastine 0.05% eye drops (Emadine® eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis
14. Council Regulation (EC) No. 2866/98 of 31 December 1998 on the conversion rates between the euro and the currencies of the Member States adopting the euro
15. Revised version of the Hannover consensus. Hannovet consensus group
16. A proposal for methodological guidelines for economic evaluation of pharmaceuticals
17. Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis. Study Group
18. Treatment of common ocular allergic disorders; A comparison of lodoxamide and NAAGA
19. Efficacy of lodoxamide 0.1% versus N-acetyl aspartyl glutamic acid 6% ophthalmic solutions in patients with vernal keratoconjunctivitis
20. Levocabastine versus cromolyn sodium in the treatment of pollen-induced conjunctivitis
21. A comparison of topical levocabastine and sodium cromoglycate in the treatment of pollen-provoked allergic conjunctivitis
22. Double-blind comparison of levocabastine eye drops with sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis
23. Topical levocabastine versus sodium cromoglycate in allergic conjunctivitis
24. Topical levocabastine is more effective than sodium cromoglycate for the prophylaxis and treatment of seasonal allergic conjunctivitis
25. Levocabastine: A new topical approach for the treatment of paediatric allergic rhinoconjunctivitis
26. Levocabastine: An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis
27. Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children
28. Economic analysis alongside clinical trials: Revisiting the methodological issues
29. Le secteur de l'ophthalmologie pharmaceutique